CIK 1993440
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 90.46% | 28 |
| Unclassified | 5.05% | 3 |
| Health Care Providers & Services | 4.50% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | UTHR | UNITED THERAPEUTICS Corp | Health Care | 6.94% |
| 2 | ABVX | Abivax S.A. | Health Care | 5.80% |
| 3 | BBIO | BridgeBio Pharma, Inc. | Health Care | 5.77% |
| 4 | XENE | Xenon Pharmaceuticals Inc. | Health Care | 5.11% |
| 5 | RVMD | Revolution Medicines, Inc. | Health Care | 5.09% |
| 6 | APGE | Apogee Therapeutics, Inc. | Health Care | 4.83% |
| 7 | INSM | INSMED Inc | Health Care | 4.54% |
| 8 | NUVL | Nuvalent, Inc. | Health Care | 4.24% |
| 9 | MIRM | Mirum Pharmaceuticals, Inc. | Health Care | 4.13% |
| 10 | COGT | Cogent Biosciences, Inc. | Health Care | 4.07% |
30/33 names classified · sector 95.0% of weight · industry 95.0% · mkt cap 87.2%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 95.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 7% of book weight classified — the grid is NOT representative of the whole book.
Classified: 6.9% of book weight (1/33 names) · unclassified 93.1%: ABVX, BBIO, XENE, RVMD, APGE, INSM, NUVL, MIRM, COGT, ROIV +22 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | UTHRUnited Therapeutics Corp. | 104,726 | $62M | 6.9% | ADD 65% |
| 2 | ABVXABIVAX SA | 465,869 | $52M | 5.8% | ADD 22% |
| 3 | BBIOBRIDGEBIO PHARMA INC | 695,718 | $52M | 5.8% | ADD 17% |
| 4 | XENEXENON PHARMACEUTICALS INC | 786,844 | $46M | 5.1% | HOLD |
| 5 | RVMDREVOLUTION MEDICINES INC | 468,376 | $46M | 5.1% | TRIM −27% |
| 6 | APGEAPOGEE THERAPEUTICS INC | 513,770 | $43M | 4.8% | ADD 8% |
| 7 | INSMINSMED INC | 248,475 | $41M | 4.5% | TRIM −6% |
| 8 | NUVLNUVALENT INC | 370,344 | $38M | 4.2% | HOLD |
| 9 | MIRMMIRUM PHARMACEUTICALS INC | 400,464 | $37M | 4.1% | TRIM −17% |
| 10 | COGTCOGENT BIOSCIENCES INC | 947,339 | $36M | 4.1% | ADD 15% |
| 11 | ROIVROIVANT SCIENCES LTD | 1,190,118 | $33M | 3.7% | HOLD |
| 12 | AXSMAXSOME THERAPEUTICS INC. | 188,772 | $32M | 3.6% | TRIM −9% |
| 13 | IDYAIDEAYA BIOSCIENCES INC | 873,838 | $29M | 3.3% | ADD 21% |
| 14 | ORICORIC PHARMACEUTICALS INC | 2,017,284 | $26M | 2.9% | HOLD |
| 15 | ELVNENLIVEN THERAPEUTICS INC | 623,839 | $24M | 2.7% | NEW |
| 16 | CELCCELCUITY INC | 210,578 | $24M | 2.7% | NEW |
| 17 | SRRKSCHOLAR ROCK HLDG CORP | 446,390 | $22M | 2.5% | TRIM −3% |
| 18 | KYMRKYMERA THERAPEUTICS INC | 254,672 | $21M | 2.4% | ADD 23% |
| 19 | CYTKCYTOKINETICS INC | 283,700 | $19M | 2.1% | TRIM −13% |
| 20 | DNTHDIANTHUS THERAPEUTICS INC | 220,921 | $19M | 2.1% | NEW |
| 21 | PVLAPALVELLA THERAPEUTICS INC | 148,093 | $18M | 2.1% | NEW |
| 22 | NAMSNEWAMSTERDAM PHARMA COMPANY | 558,336 | $18M | 2.0% | TRIM −38% |
| 23 | VRDNVIRIDIAN THERAPEUTICS INC | 911,337 | $18M | 2.0% | ADD 32% |
| 24 | ASNDASCENDIS PHARMA A/S | 76,300 | $17M | 1.9% | TRIM −42% |
| 25 | FULCFULCRUM THERAPEUTICS INC | 2,256,109 | $17M | 1.9% | ADD 19% |
| 26 | TERNS PHARMACEUTICALS INC | 326,694 | $17M | 1.9% | TRIM −63% |
| 27 | VERAVERA THERAPEUTICS INC | 422,023 | $17M | 1.9% | TRIM −30% |
| 28 | NTRANATERA INC | 81,077 | $16M | 1.8% | HOLD |
| 29 | ERASERASCA INC | 867,639 | $14M | 1.6% | NEW |
| 30 | PRAXPRAXIS PRECISION MEDICINES I | 42,441 | $14M | 1.5% | ADD 19% |
| 31 | OLMAOLEMA PHARMACEUTICALS INC | 768,662 | $11M | 1.3% | ADD 24% |
| 32 | QUREUNIQURE NV | 615,489 | $10M | 1.1% | ADD 91% |
| 33 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 315,563 | $6M | 0.7% | ADD 20% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| UTHRUnited Therapeutics Corp. | — | — | — | 85K | 64K | 105K | $62M |
| ABVXABIVAX SA | — | — | — | 292K | 381K | 466K | $52M |
| BBIOBRIDGEBIO PHARMA INC | 452K | 657K | 552K | 590K | 595K | 696K | $52M |
| XENEXENON PHARMACEUTICALS INC | 685K | 683K | 661K | 800K | 800K | 787K | $46M |
| RVMDREVOLUTION MEDICINES INC | 404K | 340K | 416K | 643K | 638K | 468K | $46M |
| APGEAPOGEE THERAPEUTICS INC | 253K | 230K | 311K | 403K | 475K | 514K | $43M |
| INSMINSMED INC | 447K | 402K | 373K | 320K | 264K | 248K | $41M |
| NUVLNUVALENT INC | 310K | 332K | 321K | 395K | 369K | 370K | $38M |
| MIRMMIRUM PHARMACEUTICALS INC | 507K | 503K | 528K | 571K | 482K | 400K | $37M |
| COGTCOGENT BIOSCIENCES INC | — | — | — | — | 824K | 947K | $36M |
| ROIVROIVANT SCIENCES LTD | — | — | — | 960K | 1.2M | 1.2M | $33M |
| AXSMAXSOME THERAPEUTICS INC. | 192K | 118K | 144K | 153K | 207K | 189K | $32M |
| IDYAIDEAYA BIOSCIENCES INC | — | — | — | — | 724K | 874K | $29M |
| ORICORIC PHARMACEUTICALS INC | 1.5M | 2.0M | 2.0M | 2.2M | 2.0M | 2.0M | $26M |
| ELVNENLIVEN THERAPEUTICS INC | 535K | 535K | 510K | 783K | — | 624K | $24M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
